ArticleProtein science : a publication of the Protein Society2026
Design and characterization of calprotectin tetramerization variants for probing the role of oligomerization in receptor activation.
Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Structural insights into zinc piracy by Neisseria gonorrhoeae to overcome nutritional immunity.Structure (London, England : 1993) · 2026Article
- Design and characterization of calprotectin tetramerization variants for probing the role of oligomerization in receptor activation.Protein science : a publication of the Protein Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Calprotectin is a heterodimer of the S100A8 and S100A9 EF-hand calcium binding proteins, which activates cell surface receptors that signal through the NF-κB inflammatory signaling pathway. Like all S100 proteins, calcium-induced conformational changes in calprotectin are required for binding to partner proteins. In the case of calprotectin, the addition of calcium correlates with the formation of a dimer of heterodimers (heterotetramer). Ligand-induced receptor oligomerization has been proposed as a mechanism of receptor activation. Conversely, it has also been suggested that calprotectin tetramerization can inhibit binding to receptors and serve as an autoinhibitory mechanism. In order to investigate the biological relevance of calprotectin tetramerization and facilitate in-depth biophysical and structural analysis, we have prepared three tetramerization-deficient variants: two single-site S100A8 mutations of hydrophobic isoleucine residues mediating the tetramer interface to lysine (I60K, I73K) and the corresponding double-site mutant (I60K/I70K). Dynamic light scattering, small-angle x-ray scattering, and nuclear magnetic resonance spectroscopy showed that all three tetramer-deficient variants remain as dimers in solution even in the presence of 40-fold excess calcium and undergo calcium-induced conformational changes. The crystal structure of I73K was determined to atomic-level resolution and confirms that the mutations cause only subtle, localized effects on the structure. Together, the results indicate that these tetramerization-deficient mutants will be useful reagents for discerning the functional role of calprotectin oligomerization in the activation of inflammatory receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.